Mineralys Therapeutics, Inc. Common Stock (MLYS) stock forecast · $2.17B cap
Mineralys Therapeutics, Inc. Common Stock (MLYS) is a biotechnology company listed on US.
This MLYS forecast page states what the cached financials imply — not a price target and not a guarantee. Mineralys Therapeutics, Inc. Common Stock outlooks on Lician start from reported revenue and the latest filing, then you decide.
No cached income statement for MLYS yet, so there is no numeric 2026 base to extend.
Period-over-period revenue change is not in cache for MLYS, so this page does not invent a growth rate.
MLYS currently screens at market cap $2.17B. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next MLYS 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the MLYS stock page.
Not investment advice.